Novel islet autoantibodies in diabetes

糖尿病中的新型胰岛自身抗体

• 批准号: 8311938
• 负责人: JOHN C HUTTON
• 金额: $ 35.6万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-01 至 2012-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8311938
• 关键词: Accounting; Adult; Age; Algorithms; Amino Acids; Ancillary Study; Antibodies; Antigens; Appearance; Archives; Attention; Autoantibodies; Autoantigens; Autoimmune Diseases; Autoimmunity; Avidity; B-Lymphocytes; Beta Cell; Biological Assay; Biological Availability; Biological Markers; Blinded; Blood Circulation; C-terminal; Cell physiology; Cells; Child; Clinical; Clinical Data; Clinical Research; DNA; Daclizumab; Detection; Development; Diabetes Mellitus; Diabetes prevention; Diagnosis; Disease; Disease Marker; Disease Progression; Effectiveness; Epitopes; Event; First Degree Relative; Future; Gender; Gene Frequency; General Population; Genetic; H(+)-K(+)-Exchanging ATPase; Haplotypes; Human; Immune; Immune Tolerance; Immune response; Immunoglobulin Class Switching; Immunologics; Immunosuppression; Individual; Insulin; Insulin-Dependent Diabetes Mellitus; Intervention Trial; Islet Cell; Laboratories; Lead; Lymphocyte; MS4A1 gene; Measures; Metabolic Control; Methods; Monitor; Natural History; Other Genetics; Outcome; Pancreas; Participant; Patient Recruitments; Patients; Positioning Attribute; Prediabetes syndrome; Predictive Value; Prevalence; Process; Proteins; Protocols documentation; Reporting; Resources; Risk; Screening procedure; Serum; Specificity; Specimen; Staging; Stratification; Surrogate Markers; Susceptibility Gene; T-Lymphocyte; Therapeutic Intervention; Therapy Clinical Trials; antigen processing; autoreactivity; base; clinical efficacy; combat; cost effective; design; disorder risk; improved; indexing; insight; insulin dependent diabetes mellitus onset; interest; islet; mycophenolate mofetil; novel; novel marker; prospective; repository; response; rituximab